Follow Eli Lilly to never miss an important update.
Lilly is expanding how patients can buy its popular weight-loss treatments, Zepbound and the oral pill Foundayo, by making them available through the Hims & Hers health platform. Patients who get a prescription from a provider on that site will pay the same out-of-pocket prices Lilly offers through its own direct channels.
This is a smart move to capture the massive group of patients whose insurance does not cover weight-loss drugs. By plugging into a popular digital health platform, Lilly makes it easier for people to get the official FDA-approved medicine rather than looking for cheaper, unapproved versions from compounding pharmacies.
Source: PRNewsWire
Lilly shared results from two large studies showing that its experimental drug, retatrutide, helped patients with obesity and knee osteoarthritis lose weight and feel significantly less pain. In some cases, patients reported having no knee pain at all by the end of the trial.
This matters because it helps Lilly prove that these drugs do more than just reduce weight. By showing they can treat specific conditions like osteoarthritis, a common type of arthritis caused by wear and tear on joints, Lilly builds a stronger case for insurance companies to cover the treatments as essential medical care.
Source: PRNewsWire
After Eli Lilly's October results, we updated our revenue and profit projections. We have added the speed of price drops for new medications and the impact of one-time research costs from acquisitions to what we track. We also reset our expectations for how quickly the company’s new weight-loss pill can win customers and how much revenue its diabetes treatments will contribute.
Lilly brought in 24.4 billion dollars in revenue this quarter, well ahead of the 22.6 billion analysts expected. The growth was led by its popular weight-loss and diabetes treatments, Mounjaro and Zepbound. The company also raised its full-year sales forecast to about 91.5 billion dollars at the midpoint, a massive 5.5 billion dollar increase from its previous outlook.
While the company took a large one-time charge for buying new drug technology, the underlying business is growing fast. The stock rose about 6 percent on the news. For long-term owners, the takeaway is that Lilly is successfully scaling its production to meet the huge global demand for its metabolic drugs.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
In a study of adults with type 2 diabetes, patients taking Lilly's experimental drug retatrutide lost about 20 percent of their body weight over 80 weeks. This was more than double the weight loss seen in patients taking the highest approved dose of Ozempic, a rival drug from Novo Nordisk. Retatrutide also did a better job of lowering blood sugar levels.
This result is important because it shows Lilly has a strong pipeline of even more effective drugs behind its current hits. By developing treatments that work better than what is on the market today, Lilly can protect its lead in the weight-loss category even as older drugs eventually face cheaper competition.
Source: PRNewsWire
Lilly has beaten its own profit targets for eight straight quarters. Management is consistently underestimating the speed at which their weight-loss drugs are taking over the market.
| Expectation | |
|---|---|
| EPS | $11.20 |
| Revenue | $24.58B |